Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Amgen, bone mineral density
Amgen speaks out about bone density concerns with obesity drug
Amgen’s stock fell 7% after an analyst posted a note on MariTide’s influence on bone density which was noticed in a data spreadsheet.
Amgen defends obesity drug amid bone concerns
After a research note raised potential safety concerns with Amgen's lead obesity candidate, the company defended its drug and has asked the journal to issue a correction and add in the finalized data.
Amgen dismisses bone density concerns related to its weight-loss drug
Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone mineral density, a day after data from an early-stage study dragged its stock 7% lower.
STAT
2d
A scrap of data on Amgen’s obesity drug candidate wipes out $12 billion in market value
On Tuesday, a tiny shred of data on
Amgen
’s lead
obesity
candidate — not yet verified — erased $12 billion in market ...
FierceBiotech
1d
Hidden data on obesity prospect wipe $12B off Amgen market cap
The tab contains data on bone density changes in patients who received
Amgen
’s
obesity
prospect MariTide in a phase 1 ...
Investor's Business Daily on MSN
1d
Amgen Drops 7% After A 'Big Unknown Risk' Rattles Its Monthly Obesity Shot
Amgen stock tumbled late Tuesday on a report that its high-profile weight-loss shot, MariTide, could be linked to bone ...
1d
Amgen slips as Cantor cites safety concerns linked to obesity candidate
Amgen (AMGN) stock falls as Cantor Fitzgerald raises safety concerns over bone mineral density loss linked to obesity ...
1d
What’s Happening With Amgen Stock?
In this photo illustration, Amgen logo is displayed on a smartphone with a S&P ... [+] index website background. (Photo ...
Benzinga.com
1d
Jim Cramer Says Eli Lilly's 'Pathetic' Stock Performance Could Get A Breather If Amgen Has Hidden Bone Risk Data After 7% Stock Drop
Amgen
Inc.‘s AMGN stock dropped over 7% on Tuesday following revelations about bone density loss in early trials of its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback